文献速递临床试验与 GCP基础与转化研究

东莨菪碱辅助新起始艾司西酞普兰治疗重性抑郁障碍:随机对照试验方案

Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-01-09

主要终点为HRSD17评分较基线改善至少20%,次要终点包括应答率、缓解率及第4周总分或子量表评分变化。研究旨在首次探讨肌注东莨菪碱辅助常规治疗在中国MDD患者中的快速抗抑郁疗效和耐受性。

要点

  • 肌注东莨菪碱辅助艾司西酞普兰可能加速早期抗抑郁疗效。
  • 主要终点为HRSD17评分较基线至少20%改善。
  • 研究为单中心、小样本试点,需更大规模试验验证。

核心结论

  • 研究将首次评估肌注东莨菪碱辅助艾司西酞普兰在中国MDD患者中的快速抗抑郁疗效和耐受性。

主要发现

  • 主要终点为HRSD17评分较基线至少20%改善。
  • 预设次要终点包括应答率、缓解率及基线至第4周总分或子量表评分变化。

关键数值与推荐

  • 主要终点:HRSD17评分较基线至少降低20%。
  • 次要终点:应答率、缓解率及基线至第4周总分或子量表评分变化。

临床怎么用

  • 若验证有效,肌注东莨菪碱辅助治疗可能为MDD患者提供快速起效的增效策略。

局限性

  • 样本量小且为单中心研究,需更大规模试验进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Major depressive disorder (MDD) is a prevalent and disabling disorder that can lead to heavy individual, familial, and societal burdens. Although pharmaceutical interventions still play an essential role in therapeutic measures, limitations, including effects that are delayed for weeks, are noteworthy. Antidepressants with rapid efficacy and acceptable tolerance have been investigated for many years; rapid antidepressant effects and promising clinical applications have been obtained with intravenous and oral scopolamine. This study aims to evaluate the efficacy of repeated intramuscular scopolamine as an add-on treatment to escitalopram. METHODS: This is a single-center, saline-controlled, double-blind, three-armed, randomized trial. Sixty-six participants diagnosed with MDD will be recruited at Beijing Anding Hospital and randomly assigned to one of three groups: a high-dose intramuscular scopolamine augmentation group; a low-dose intramuscular scopolamine augmentation group; and a placebo control group. Our primary endpoint is improvement in the 17-Item Hamilton Rating Scale for Depression (HRSD17) score from the baseline (at least a 20% reduction). Prespecified secondary endpoints include response rates and remission rates as well as changes in the total or subscale scores between the baseline and week 4. DISCUSSION: This study will provide the first insight regarding the rapid antidepressant efficacy and tolerability of an intramuscular scopolamine add-on to the usual treatment in Chinese MDD patients. The first discussion concerns whether augmentation can accelerate early antidepressant efficacy. A pilot study of intramuscular scopolamine is performed. The limitations of this study include its small sample size and it being a single-center study, suggesting the need for further confirmation with trials enrolling larger populations. ETHICS AND DISSEMINATION: The study protocol and all related materials have been approved by the Institutional Ethics Committee of the Beijing Anding Hospital (No. 2016-106, Beijing, China). The findings will be disseminated through peer-reviewed journals and at national and international conferences. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03131050 . Registered on 18 April 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhou J, Wang W, Yang J, et al. Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial. Trials. 2019. PMID: 30626409. doi:10.1186/s13063-018-3132-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。